8-K: Annovis Bio Faces NYSE Delisting Warning

Annovis Bio, Inc. received a notice from the NYSE for failing to meet continued listing standards, triggering a 9-month cure period to submit a compliance plan.

Summary

• Annovis Bio, Inc. received a notice from the New York Stock Exchange (NYSE) on October 29, 2026, stating it is no longer in compliance with continued listing standards.
• The non-compliance is due to the company's average market capitalization over 30 trading days being below $50 million and its stockholders' equity also being below $50 million.
• As of October 28, 2026, the 30-day average market capitalization was approximately $48.4 million, and stockholders' deficit as of June 30, 2026, was approximately $(4.3) million.
• The company has 45 days to submit a plan to the NYSE detailing actions to regain compliance within 9 months.
• If the plan is not submitted or accepted, delisting proceedings will commence.
• The common stock will continue to trade under the symbol ANVS, but with a '.BC' designation indicating its below-criteria status.
• This notice does not impact business operations or debt agreements.
• The company is a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases like Alzheimer's and Parkinson's.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the NYSE non-compliance notice, indicating potential delisting risks and financial distress, despite the company's efforts to present a plan for remediation.

Positives

• The company has a 9-month cure period to submit and execute a plan to regain compliance with NYSE listing standards.
• The notice has no immediate impact on the listing of the company's common stock, which will continue to trade on the NYSE.
• The notice does not affect the company's business operations or its reporting obligations with the SEC.
• The notice does not conflict with or cause an event of default under any of the company's material debt or other agreements.

Negatives

• Annovis Bio is not in compliance with NYSE continued listing standards (Section 802.01B).
• The company's 30-day average market capitalization was below $50 million ($48.4 million as of Oct 28, 2026).
• The company's stockholders' equity was below $50 million ($(4.3) million deficit as of June 30, 2026).
• Failure to submit or gain acceptance of a compliance plan could lead to delisting proceedings.
• The common stock trading symbol will have a '.BC' designation, indicating below-criteria status.

Risks

• Risk of delisting from the NYSE if a compliance plan is not submitted, accepted, or successfully executed within 9 months.
• Potential for accelerated delisting if the common stock trades at abnormally low levels (generally below $0.10).
• Uncertainty regarding the NYSE's acceptance of the company's compliance plan.
• The company's ability to execute the compliance plan and meet continued listing standards within the cure period.
• Risks arising from the potential suspension of trading of the company's common stock on the NYSE.

Future Outlook

The company is actively working on a plan to regain compliance with NYSE continued listing standards within a 9-month cure period. The success of this plan and the NYSE's acceptance are critical for continued listing.

Management Comments

• The Notice has no immediate impact on the listing of the Companys common stock, which will continue to be listed and traded on the NYSE during the cure period.
• The Company has notified the NYSE that it will submit a plan within 45 days of the Notice advising the NYSE of definitive action it has taken, or is taking, to bring it into conformity with Section 802.01B within 9 months of receipt of the Notice.

Industry Context

StockSavvy.ai notes that biotechnology companies, especially those in clinical stages, often face volatility in market capitalization. Non-compliance with exchange listing standards due to low market cap is a recurring challenge for companies in this sector, particularly when clinical trial results or funding concerns arise.

Stakeholder Impact

• Shareholders: Potential for increased volatility and uncertainty regarding the stock's listing status, which could negatively impact share price. The '.BC' designation may also deter some investors.
• Creditors: While current debt agreements are not affected, a delisting could impact the company's ability to secure future financing or renegotiate terms.
• Employees: Uncertainty about the company's future stability could impact morale and retention.

Next Steps

• Submit a plan to the NYSE within 45 days of the Notice (by November 12, 2026) detailing actions to regain compliance.
• The NYSE will review the plan and make a determination within 45 days of submission (by January 29, 2027).
• If the plan is accepted, the company will have 9 months (until October 29, 2027) to regain compliance.
• The company will be reviewed semi-annually by the NYSE to confirm compliance with the plan.
• The common stock trading symbol will have a '.BC' designation until compliance is regained.

Key Dates

Recommendation

The filing indicates a significant risk of delisting from the NYSE due to failure to meet continued listing standards. While the company has a cure period and a plan to address this, the underlying financial metrics (low market cap and negative equity) suggest underlying business challenges. The outcome of the compliance plan is uncertain. Therefore, a 'hold' recommendation is appropriate, pending further developments on the compliance plan and the company's ability to execute it, alongside its core business progress.

Keywords

NYSE listing standards, delisting, market capitalization, stockholders equity, compliance plan, biotechnology, neurodegenerative diseases, buntanetap